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Leveraging Aqueous Humor Dynamics and Ocular Biometrics for
Improving Therapeutic Outcomes in Glaucoma
Vikas Gulati M.D., Ph.D.
University of Nebraska, 2020

Glaucoma laser and incisional surgical treatments are associated with a known risk of
complications. The ability to better predict treatment outcomes and individualize treatment
recommendations can enhance the benefit to risk ratio of a treatment option. The work
presented in this dissertation explores the interplay of biometrics, race and aqueous humor
dynamics and their influence on treatment outcomes. In the first chapter, we demonstrate that
pre-operative aqueous humor dynamics (higher aqueous flow, lower outflow facility and lower
uveoscleral outflow) are predictive of greater intraocular pressure lowering after selective laser
trabeculoplasty. The second chapter describes significant race-based differences in aqueous
humor dynamics and biometrics between a Chinese and Caucasian study set, each compromised
of two different age groups. Overall, Chinese subjects had a higher intraocular pressure, higher
aqueous flow, lower uveoscleral outflow, higher outflow facility, lower anterior chamber volume
and higher central corneal thickness as compared to Caucasian subjects. The final chapter
demonstrates that the intraocular pressure lowering effects of a trabecular bypass procedure
(iStent) are much less apparent in non-Caucasian patients and in patients with higher axial
lengths. Cataract surgery done without iStent, had greater success in eyes with flatter
keratometry, deeper anterior chamber and shorter axial lengths. This work thereby identifies
significant interplay between race, biometrics and aqueous humor dynamics and describes their
influence on glaucoma treatment outcomes.
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Background
Glaucoma is a one of the leading causes of blindness in the US and worldwide. It affects over 2
million people in the US1 and over 60 million globally.2 More than half of glaucoma is
undiagnosed.3-6 Unlike cataract, vision loss from glaucoma is irreversible with lasting functional
consequences for the patients.7-9
Glaucoma can be broadly divided into open angle and angle closure types, depending largely
upon whether there is a mechanical obstruction to the flow of aqueous humor to the trabecular
meshwork. Presence of such an obstruction, most commonly with iris tissue implies the angle
closure mechanism. According to the American Academy of Ophthalmology definition, primary
open-angle glaucoma (POAG) is a progressive, chronic optic neuropathy in adults in which
intraocular pressure (IOP) and other currently unknown factors contribute to damage and in
which, in the absence of other identifiable causes, there is a characteristic acquired atrophy of
the optic nerve and loss of retinal ganglion cells and their axons.10 Even though IOP is just a risk
factor for glaucoma, currently it is the only treatable clinical parameter that can prevent further
vision loss in glaucoma.11-14 The modified Goldmann equation (Eq 1) summarizes the relationship
between the parameters of aqueous humor dynamics (AHD) that determine the IOP in health
and disease states.
IOP = (Aqueous inflow-Uveoscleral outflow)/outflow facility + episcleral venous pressure
(Eq 1)
Aqueous humor is produced by the ciliary body and egresses the eye through trabecular and
uveoscleral outflow. The pressure head required to maintain outflow through the trabecular
pathway to maintain the equilibrium between aqueous inflow and outflow translates into the
IOP. Outflow facility is the inverse of the resistance in the trabecular outflow pathway, also
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referred to as the conventional outflow pathway. All these parameters can be measured using
techniques utilized in the research included in this dissertation.
Aqueous inflow (or aqueous flow as is the traditional label) is measured by fluorophotometry.
This technique entails administration of fluorescein drops to the eye in preparation for the
experiments and waiting enough time (4-6 hours) to reach a stable level in the cornea and
anterior chamber. Hourly measurements of fluorescein levels in the cornea and anterior
chamber using a scanning fluorophotometer can be used to plot a decay curve over time and
calculate the aqueous flow in the eye. 15
Episcleral venous pressure is the downstream pressure for aqueous flow through the trabecular
pathway and is believed to represent the outflow recipient pressure in the conventional outflow
flow system of the eye. It is measured using a episcleral venomanometer whereby a silicon
membrane connected to a variable pressure chamber is used to apply pressure to a visible
episcleral vein on the eye under direct visualization.16 Somewhat similar to blood pressure
measurement, the episcleral venous pressure is deemed to be the pressure required to initiate
the visible collapse of a selected episcleral vein on the ocular surface.
Outflow facility can be measured using 2 different techniques: fluorophotometry and
tonography. Both methods were used in the research described herein. In the
fluorophotometric method17, baseline aqueous flow and IOP are measured. An aqueous
suppressant medication such as topical timolol or systemic acetazolamide is administered
followed by a repeat assessment of aqueous flow and IOP. The use of these drugs is driven by
the fact that they are believed to have no effect on any of the other parameters of AHD.
Outflow facility is calculated as the ratio of change in aqueous flow to the change in IOP. In the
tonographic method, gentle pressure is applied to the eye using a weighted tonometer probe
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for a period of 2-4 minutes. The decrease in IOP under artificially raised pressure is captured
during the 2-4 minutes. Using the change in IOP and from known pressure/volume data for the
eye (published elsewhere), the additional fluid expressed out of the eye is estimated and
outflow facility is calculated using mathematical formulas. 18
Uveoscleral outflow, also known as unconventional outflow, is a poorly defined aqueous egress
pathway in the eye. This outflow is described as pressure independent because the flow rate
does not change in the pressure range of normal to high. The flow occurs across the ciliary body
face and in many directions thereafter including the suprachoroidal space. It cannot be directly
measured noninvasively. It is mathematically calculated using the above Goldmann equation by
plugging in all variables other than uveoscleral outflow.
Elevated IOP in primary open angle glaucoma is believed to be a consequence of increased
resistance in the outflow pathways at the level of the juxtacanalicular tissue.19,20 In terms of
parameters of AHD, elevated IOP in ocular hypertensive patients is related to lower outflow
facility and slower uveoscleral outflow.21 Medical therapy lowers IOP by targeting one or more
of the parameters of AHD. An assessment of AHD can provide valuable information on the
mechanism of action of medications and some surgical interventions.

Ocular Biometrics

Like AHD, ocular biometrics can play a role in the mechanism of certain types of glaucomas and
can have a potential effect on therapeutic outcomes as well. For example, shorter eyes are more
likely to have narrow angle glaucoma and longer myopic eyes are more likely to have a type of
glaucoma called pigmentary glaucoma. The biometrics parameters that can be measured
clinically, include the curvature of the cornea, thickness of the cornea, distance between the
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cornea and the anterior lens surface (anterior chamber depth) and the total antero-posterior
length of the eyeball (axial length). Research included here explores the racial differences in
biometric parameters and the influence of these parameters on surgical outcomes.

Laser Surgery for Glaucoma
Besides topical medications laser trabeculoplasty is another option for treatment of elevated
IOP.22,23 Laser trabeculoplasty delivers laser energy to the trabecular meshwork using a
gonioprism in an attempt to lower the IOP. An earlier iteration of this procedure used argon
laser, which has photocoagulative effects on the target tissues. Using the argon laser, the
Glaucoma Laser Trial (GLT) has shown laser trabeculoplasty to be better than topical
medications at visual field preservation and IOP lowering as primary therapy.24,25 Currently most
trabeculoplasties are performed using frequency doubled Nd:YAG laser rather the argon laser
used in the GLT study. Trabeculoplasty performed using this laser, also known as selective laser
trabeculoplasty (SLT), does not have any photocoagulative effects unlike argon laser and can be
speculated to have a mechanism of action entirely different from argon laser trabeculoplasty.
The research reported here is the first comprehensive study of the mechanism of action of SLT.

Baseline AHD and Therapeutic Outcomes
There are no prior reports on the influence of baseline AHD on IOP lowering outcomes by any
medical or surgical intervention. One of the objectives of this research was to evaluate if
preoperative AHD can be predictive of treatment outcomes after selective laser trabeculoplasty.
Any associations seen may help leverage baseline AHD to guide treatment to maximize the
efficacy and minimize the exposure to unwanted adverse events associated with the laser
procedure.
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Race and AHD
There is a scarcity of prior reports on racial differences in AHD. The prevalence of different types
of glaucoma can vary across different racial backgrounds.26-30 Primary open-angle glaucoma is
much more prevalent in subjects of African and Latino descent whereas angle closure glaucoma
is more prevalent in Asian subjects. If treatment outcomes are influenced by race and AHD it will
be useful to study the systematic racial differences in AHD. These racial differences in AHD and
their effect on treatment outcomes can then be targeted to better understand the mediators of
treatment success and improve treatment outcomes in glaucoma. Part of the research
described herein evaluates age and race-based differences between Chinese and Caucasian
study populations.

Race and Surgical Treatment Outcomes
Conventional glaucoma procedures include trabeculectomy and glaucoma drainage devices.
Trabeculectomy creates a fistula between the anterior chamber and the space under the
conjunctiva and Tenon’s capsule. Drainage devices involve placing a plate made of silicone or
other material in this space connected to a tube that communicates between the anterior
chamber and this plate. Both these procedures can fail as a result of scarring in the
subconjunctival space. A higher rate of failure with traditional glaucoma surgeries such as
trabeculectomies and glaucoma drainage devices among blacks is well known.31-33 The
difference may be due to different healing and scarring responses in the conjunctiva and
Tenon’s space among different races.31 Newer glaucoma procedures such as the iStent34 and
Hydrus implant35 do not involve the subconjunctival space and should not be subject to the
perils of scarring in the subconjunctival space. The last study described herein evaluates if the
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success of trabecular bypass procedures is affected by race. Specifically, we aim to evaluate if
there is a difference in the IOP lowering outcomes with an FDA approved trabecular bypass
device (iStent) between Caucasian and non-Caucasian subjects. The said device is only approved
for use in conjunction with cataract surgery which by itself is well known to lower IOP for years
after the procedure.36 To control for the IOP lowering effect of cataract surgery and its
interaction with race, a race based comparison is also performed for the IOP lowering effect of
standalone cataract surgery. In addition, other clinical and demographic variables were utilized
in the multivariate models to explore potential predictors of surgical success and failure.
A future goal of this research is to study the effect of aqueous humor dynamics on the outcomes
of trabecular bypass surgical procedures. This research provides evidence supporting the
influence of aqueous humor dynamics and race on IOP lowering procedures. It also
demonstrates that aqueous humor dynamics and ocular biometrics, that influence surgical
outcomes, are themselves affected by race. Therefore, a comprehensive race-based study of
ocular biometrics and AHD can provide valuable insights into the mediators of success after
surgical IOP lowering interventions.
Research included in this dissertation has the following 3 sections:
1. The first paper describes the mechanism of IOP lowering for selective laser
trabeculoplasty and provides evidence that preoperative aqueous humor dynamics can
be predictive of treatment outcomes.
2. The second paper compares aqueous humor dynamics and biometrics between a
Caucasian and a Chinese population to provide evidence that biometrics, AHD and
changes therein with aging vary across different racial backgrounds.
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3. The third paper provides evidence that race and other biometric parameters correlate
with IOP lowering outcomes of cataract surgery and a novel trabecular bypass
procedure.

Impact
At this time there are no known clinical or physiological parameters that correlate with the IOP
lowering effect of laser and surgical procedures. Practice patterns vary widely among clinicians.
This approach is not only inefficient but may also be cost ineffective. It may expose some
patients to the risk of an additional procedure without a potential benefit or may miss the onetime opportunity for potential IOP lowering using stents with less or no medications.
This work addresses several unmet needs to lay the groundwork for personalization of surgical
management of mild to moderate glaucomas. This study is a step forward in the direction of
precision medicine. Future predictive models evolving from the results of this work can help
guide treatment choices for individual patients based on their individual risk factors.
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Chapter One: Mechanism of Action of Selective Laser
Trabeculoplasty and Predictors of Response
At the time of this research there were no prior comprehensive studies on the mechanism of
action of selective laser trabeculoplasty. The assumptions of mechanism of action of SLT were
derived from prior work on argon laser trabeculoplasty. SLT unlike ALT does not have any photocoagulative effects and may have a completely different effect on AHD as compared to ALT.
Additionally, to the best of our knowledge there were no prior reports on any association
between pre-operative AHD and post-operative outcomes. The following research was directly
supported by the American Glaucoma Society Clinician Scientist Award and has been published
in Investigative Ophthalmology and Visual Sciences.37
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Abstract
Purpose: This study was designed to evaluate the changes in aqueous humor dynamics (AHD)
produced by selective laser trabeculoplasty (SLT) and to explore if baseline AHD parameters are
predictive of intraocular pressure (IOP) response to SLT.
Methods: Thirty-one consecutive subjects diagnosed with ocular hypertension or primary openangle glaucoma scheduled to undergo SLT as their primary IOP lowering therapy were enrolled
in this prospective observational study. Subjects underwent baseline assessment of AHD in both
eyes. Variables assessed were IOPs at 9AM and noon, aqueous humor flow
rate(fluorophotometry), episcleral venous pressure (EVP, venomanometry), outflow facility
(pneumatonography and fluorophotometry) and uveoscleral outflow (calculated using modified
Goldmann equation). All subjects underwent 360 degrees SLT and AHD measurements were
repeated 3 months later.
Results: Compared to baseline, IOPs after SLT were significantly lower at 9AM (22.9±5.1mmHg
vs. 19.7±3.0 mmHg; p=0.001) and noon (23.4±4.6 mmHg vs. 20.0±3.5 mmHg; p<0.001). Outflow
facility by fluorophotometry was significantly increased from 0.17±0.11 µl/min/mmHg at
baseline to 0.24±0.14 µl/min/mmHg at 3 months (p=0.008). Outflow facility by tonography
(baseline: 0.16±0.07 µl/min/mmHg vs. 3-months: 0.22±0.16 µl/min/mmHg; p=0.046) was
similarly increased. No change in aqueous flow or EVP was observed. There were no changes in
IOP or AHD in the contralateral untreated eye. Using multiple linear regression models, higher
baseline aqueous flow, lower baseline outflow facility and possibly lower uveoscleral outflow
were associated with more IOP lowering with SLT.
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Conclusions: The IOP lowering effect of SLT is mediated through an increase in outflow facility.
There is no contralateral effect. Higher aqueous flow and lower outflow facility may be
predictive of better response to SLT.
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Introduction
Lowering of intraocular pressure (IOP) is currently the only well-established treatment strategy
for management of ocular hypertension (OHT)38 and glaucoma.12-14 Laser trabeculoplasty is
extensively utilized as a primary or adjunctive therapy for lowering the IOP in OHT, glaucoma
suspects, and patients with primary and several secondary open angle glaucomas. Introduction
of selective laser trabeculoplasty (SLT) in the late 1990s22 has resulted in a significant increase in
the number of trabeculoplasties performed in the past decade.39-41 The IOP lowering effect of
argon laser trabeculoplasty (ALT) is mediated through an increase in conventional outflow
facility,42 which in turn may be mechanically or biologically mediated after the delivery of laser
to the anterior chamber angle structures.43-45 As SLT delivers about 1% of total energy used by a
typical ALT and does not have any thermal coagulative effects like ALT,46 it purportedly can have
a mechanism of action different from ALT. Prior reports have shown an increase in conventional
outflow facility at 1 and 3 months and no effect on aqueous humor inflow rate at 3 months after
SLT.47,48 These are two important parameters of aqueous humor dynamics (AHD), changes in
which alter IOP. Other parameters important in regulating IOP but with unknown roles in the
IOP responses to SLT treatment are episcleral venous pressure (EVP) and uveoscleral outflow.
This is the first comprehensive study of the effects of SLT on all parameters of AHD in the same
patients. Additionally, this study presents a multiple regression analysis of patient, treatment,
and AHD variables to identify potential predictors of IOP response to SLT.

Methods
This prospective study, conducted at a tertiary care academic practice, enrolled consecutive
patients undergoing primary SLT with a clinical diagnosis of either OHT, glaucoma suspect or
primary open angle glaucoma. The study followed the tenets of the Declaration of Helsinki and
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was approved by the Institutional Review Board of the University of Nebraska Medical Center.
Primary therapy for the purpose of the study was defined as SLT being considered as the only
IOP lowering modality whether or not patients have used IOP lowering medications in the past.
Subjects considered for the study were those interested in SLT as primary 1st line therapy, those
with a preference to discontinue current medication(s) for concerns such as side effects and
medication cost and those who were recommended SLT due to past poor compliance with
medication use. After the patient agreed to proceed with SLT, they were approached for
participation in this study. A total of 31 of 35 consecutive subjects agreed to participate in the
study and gave informed consent.
Participating subjects underwent a screening visit comprising of a detailed anterior segment
examination including dynamic gonioscopy, and a dilated fundus examination. A subjective
assessment was made of angle pigmentation on a scale of 0 to 4. Inclusion criteria consisted of
subjects with a clinical diagnosis of OHT, glaucoma suspect or primary open angle glaucoma
undergoing primary SLT (as defined above) who were either not on any medications or could be
safely washed out of a single topical medication. Subjects were excluded if they had a history of
prior ocular incisional surgical procedures, known history of past laser trabeculoplasty, corneal
opacity precluding fluorophotometry, use of topical or systemic steroids within 3 months of the
study, narrow angle (scleral spur not visible for greater than 180 degrees without pressure on
dynamic gonioscopy), secondary open angle glaucoma (exfoliation, pigment dispersion or angle
recession glaucoma), and known allergy to fluorescein, proparacaine or sulfa medications.
Subjects with a diagnosis associated with potential retinal ischemia (diabetic retinopathy or
retinal arterial or vein occlusion) also were excluded from the study.
Of the 31 enrolled subjects, none were excluded from participation at the screening visit.
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Enrolled subjects on a topical medication at the time of screening started a washout in both
eyes, after approving the safety of the washout with the treating physician. For subjects who
had stopped the topical medication prior to the screening visit, washout was deemed to start at
the reported time point of stopping the medication. Of the eight subjects that underwent
washout before baseline measurements were made, 7 were using a prostaglandin analog in
both eyes and one was using a carbonic anhydrase inhibitor in both eyes. Washout for a
prostaglandin analog was a minimum of 4 weeks and that for the carbonic anhydrase inhibitor
was 1 week. During the washout period IOP was monitored every 2 weeks. The actual median
washout in the study was 7 weeks (range 4 to 11 weeks).
Subsequent to the screening visit and any required washout, subjects underwent a baseline
assessment of AHD. Standard techniques for AHD measurement and the underlying assumptions
have been reported previously.15 For the purpose of fluorophotometry, subjects self-instilled 8
drops of sodium fluorescein at 10 pm the night before each scheduled visit. On the study day,
central cornea thickness and anterior chamber depth were measured by ultrasound pachymetry
and A-scan respectively. Seated IOP was measured by pneumatonometer (performed by SF, CBT
or DGN, masked to treatment plan) at 9 AM, followed by hourly fluorophotometry scans until
noon. IOP measurement was repeated at noon. EVP was measured at 10 am using an episcleral
venomanometer.49 For both EVP and IOP, 2 measurements were obtained for each eye. A third
measurement was obtained if the first 2 differed by more than 2 mm Hg. The median value for
each eye was used for analysis. The rate of fluorescein decay in the cornea and anterior
chamber was used to calculate the aqueous humor flow rate.15 Subjects were given 500 mg of
acetazolamide at noon. Three additional hourly fluorescein scans and IOP measurements were
obtained after acetazolamide administration. Outflow facility was calculated as the ratio of
change in flow to change in IOP accomplished by acetazolamide. Two minute
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pneumatonography was performed at 3 pm after all other measurements were completed. IOP
data during tonography was captured digitally at 40 Hz using Powerlab and Lab Chart 7
software. The starting and ending IOP were deduced using regression techniques previously
described.50,51 Pressure volume relationship data for the human eye were thereby used to
calculate the outflow facility by tonography.18 Uveoscleral outflow was calculated with the
modified Goldmann equation, by using the outflow facility obtained by fluorophotometry and
tonography, respectively. Data were obtained from all study eyes and the contralateral
untreated eyes that met the inclusion and exclusion criteria.
The study eye underwent SLT within 1 week of obtaining baseline measurements.
Preoperatively, all subjects received one drop each of pilocarpine 2% and brimonidine 0.2%.
Goldmann lens was used to perform all trabeculoplasties. A total of 80 spots were placed over
360 degrees of the anterior chamber angle. Laser power was titrated starting at 0.8 mJ (with the
exception of one case with excessive angle pigment), to 0.1mJ below the minimum required to
generate ‘champagne bubbles’ at the application site. A subjective estimate of the percentage
of applied laser spots associated with champagne bubbles was recorded by the treating
physician (VG) in the patient chart. IOP was checked one hour after the laser treatment and the
patients were provided with a non-steroidal anti-inflammatory drop to use if needed for relief of
ocular pain and discomfort.
Following SLT two subjects required topical IOP lowering medications in the study eye (1
prostaglandin analog, 1 carbonic anhydrase inhibitor), and 4 subjects required IOP lowering
medications in the fellow control eye (3 prostaglandin analogs, 1 carbonic anhydrase inhibitor)
in the post-operative period. All medications were washed out using the protocol described
above prior to obtaining the 3 months follow up study measurements.
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Three months after the SLT, the subjects underwent repeat assessment of all AHD variables
obtained at the baseline visit.

Statistical Analysis
Descriptive statistics were calculated for all data. Data are presented as mean ± standard
deviation unless indicated otherwise. The primary comparison was made for the IOP and AHD
data obtained in the study eye between baseline and 3 months after the laser treatment using
paired t-tests. Sample size was calculated based on changes in outflow facility which was the
leading hypothesis prior to the conduct of the study. With an expected change in outflow facility
of 0.05 µl/min/mmHg and presumed standard deviation of 0.09 µl/min/mmHg for the change,42
a sample of 27 subjects would have 80% power to detect such a difference at an alpha of 0.05.
Multiple linear regression was used to study the association between baseline AHD,
demographic and treatment parameters and IOP response. Three separate regression models
were constructed; one based on parameters of aqueous humor dynamics (aqueous flow, EVP,
outflow facility and uveoscleral outflow), the second based on patient demographic variables
(age, sex, race and central corneal thickness) and the third based on variables relevant to laser
tissue interaction (angle pigmentation, total laser energy used and percentage of spots with
bubble formation). A stepwise backward elimination approach was used to develop the model,
discarding associations with p value less than 0.05 until all remaining covariates in the model
had a p value less than 0.05. Interactions were not included in the model to limit the covariates
given the small sample size. The outcome variable for both models was mean change (mean for
9 AM and 12 noon) in IOP. Multiple regression analysis also was performed using the percentage
change in IOP as the outcome variable (rather than absolute change in IOP). A P value of less
than 0.05 was consider statistically significant.
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Results
A total of 31 subjects who consented for the study, underwent a screening visit. Eleven subjects
had opted for SLT as first line therapy, 12 had used medications in the past but were pursuing
SLT because of issues with medications such as cost and side effects and 8 were recommended
to undergo SLT because of poor compliance with recommended medications. In terms of the
clinical profiles, enrolled subjects included 5 subjects with 2 or more IOPs above 24 with no
glaucomatous cupping or visual field defect, 16 with glaucomatous cupping (as determined by
the treating physician) without any visual field defect, and 10 with repeatable (2 or more
occasions) visual field defects with supportive optic nerve head appearance. The IOP targets set
by the treating physician for the subjects consented for the study were mid-teens (n=1), high
teens (n=7), low 20s (n=10) and mid 20s (n=13).
Of the 31 subjects enrolled, 29 completed all study related measurements, one was lost to
follow up after the SLT and one was unable to adequately administer fluorescein for
fluorophotometry on scheduled baseline visits on two different days. The latter subject was
withdrawn from the study and underwent SLT as planned. Four contralateral eyes also were
excluded from analysis. Three of these were pseudophakic and one had previously undergone
laser trabeculoplasty. Data were analyzed for 29 subjects, comprising 29 study eyes and 25
contralateral eyes.
Mean age of the study population was 64.0 ± 9.3 years (range 48-79 years). Eleven subjects
were females. Based on self-reported race, 15 subjects were Caucasian, 12 were African
Americans and 1 each were Hispanic and Asian.
Baseline and 3 month AHD data are summarized in Table 1. Post SLT, there was a significant
decrease in both the 9 am and 12 noon IOP in the SLT treated eye, with no change in IOP in the
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contralateral control eye. There was no change in aqueous flow or EVP in either the treated or
contralateral eye, 3 months after treatment. Outflow facility (by fluorophotometry) was
significantly increased from 0.17 ± 0.11 µl/min/mmHg at baseline to 0.24 ± 0.14 µl/min/mmHg
at 3 months after treatment (p=0.008). The outflow facility in the contralateral eye was
unchanged. The change in outflow facility was reproducible on tonography increasing from 0.16
± 0.07 µl/min/mmHg at baseline to 0.22 ± 0.16 µl/min/mmHg at 3 months (p=0.046).
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Table 1: Aqueous humor dynamics parameters at baseline and 3 months after selective laser trabeculoplasty in the treated eye and contralateral control eye.
Variable
IOP (9 AM, mmHg)
IOP (Noon, mmHg)
Aqueous flow (µl/min)
EVP (mmHg)
Outflow facility (fluorophotometry,
µl/min/mmHg)
Outflow facility (tonography,
µl/min/mmHg)

Treated Eye (n=29)
Baseline
3 months
22.91 ± 5.12 19.67 ± 3.00
23.43 ± 4.60 20.00 ± 3.45
2.51 ± 1.11
2.27 ± 0.84
9.74 ± 1.46
9.61 ± 1.12
0.17 ± 0.11
0.16 ± 0.07

p
0.001
<0.001
0.16
0.64

Control Eye (n=25)
Baseline
3 months
21.60 ± 4.80 21.83 ± 3.20
21.53 ± 4.61 21.42 ± 3.49
2.60 ± 1.45
2.33 ± 1.00
9.89 ± 1.09
9.35 ± 1.30

p

Treated vs Control (n=25)
Baseline
3 months
0.01
0.001
0.01
0.01
0.47
0.51
0.62
0.54

0.79
0.87
0.28
0.07

0.24 ± 0.14

0.008

0.24 ± 0.16

0.22 ± 0.20

0.74*

0.01*

0.85

0.22 ± 0.16

0.046

0.18 ± 0.07

0.20 ± 0.12

0.53

0.18

0.73

*n=24 (subject excluded because of undetectable change in IOP with acetazolamide precluding outflow facility calculation). P values obtained using paired t-test.
IOP=intraocular pressure; EVP=episcleral venous pressure
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Three months after SLT treatment, uveoscleral outflow in the treated eye was lower by
0.36 ± 0.94 µl/min when calculated using fluorophotometry data (p=0.05), but not when
using tonography data (Δ=-0.26±2.15 µl/min, p=0.52). At the same time, no change in
uveoscleral outflow was detected in the contralateral untreated eye. These results are
summarized in Figure 1.
Figure 1: Change in uveoscleral outflow at 3 months after selective laser trabeculoplasty
in the treated (n=29) and contralateral control eyes (n=24 for fluorophotometry, 25 for
tonography)

Values on the plot indicate mean ± SD. Error bars = one standard error.
p-values calculated using paired t-test

Responder Analysis
To further validate the ‘cause-effect’ hypothesis of change in fluorophotometric outflow
facility being the mediator of IOP lowering seen with SLT, secondary analysis of the
variable was conducted using a binary categorization of subjects as responders and nonresponders (Figure 2). When IOP response was defined as 10% or more IOP lowering at
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either 9 AM or noon, a statistically significant increase in outflow facility was
reproducible with greater confidence (p=0.004) in IOP responders (n=20). The outflow
facility in IOP non-responders was unchanged (n=9, p=0.90). If the definition of response
was changed to 10% or greater IOP lowering for both the 9AM and noon IOP, the
confidence in increase in outflow facility increased further in IOP responders (p=0.0003,
n=15). The outflow facility was unchanged in IOP non-responders by this definition as
well (p=0.84). Scatter plot of change in IOP plotted against change in outflow facility for
the lasered and contralateral eye (Figure 3) was suggestive of a linear relationship in the
lasered eye and no correlation in the contralateral eye. The Spearman correlation
coefficient was statistically significant for lasered eyes (σ =-0.41, p=0.03) but not for
control eyes (σ =0.21, p=0.34).
Figure 2: Change in outflow facility at 3 months in lasered and contralateral control eyes
categorized based on percentage IOP lowering from baseline with selective laser
trabeculoplasty.

Values on the bars are mean ± SD. Error bars = one standard error.
p-values calculated using paired t-test
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Figure 3: Scatter plot of change in intraocular pressure against change in
fluorophotometric outflow facility in lasered and contralateral eyes. Scatter plot of
change in intraocular pressure against change in fluorophotometric outflow facility in
lasered and contralateral eyes. IOP change is the average of change at 9 am and noon
for each subject. The Spearman σ for the correlation in lasered eyes was -0.41 (p=0.03)
and that in contralateral untreated eyes was 0.21 (p=0.34).

Predictors of Response

Using change in IOP as the outcome variable, baseline demographic, treatment and AHD
variables were analyzed as covariates using multiple linear regression models (Table 2).
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Table 2: Results of multiple linear regression analysis with IOP response (IOP at 3
months-baseline IOP) as outcome variable.
Model 1a
Fluorophotometry
Data
Aqueous Flow
Outflow Facility
Model 1b
Tonography Data
Aqueous Flow
Outflow Facility
Uveoscleral outflow
Model 2
Patient Variables
Age
CCT

Coefficient (SE)

P value

2.377 (0.749)
-26.822 (7.684)

0.004
0.002

4.170 (0.966)
-51.509 (11.383)
-3.003 (0.735)

<0.001
<0.001
<0.001

-0.182 (0.090)
-0.044 (0.024)

0.052
0.076

ANOVA p
0.003

<0.001

0.08

SE=standard error
IOP response (outcome) was the average of the response at 9 am and 12 noon.
Model 1a included episcleral venous pressure (p=0.64) and uveoscleral outflow
(fluorophotometric) (p=0.48) in the initial model.
Model 1b included episcleral venous pressure (p=0.06) in the initial model.
Model 2 included sex (p=0.41) and race (p=0.69) in the initial model.

Outflow facility and uveoscleral outflow were assessed in this study using 2 different
methods, fluorophotometry and tonography. Therefore, the multiple regression model
using AHD parameters was run separately for the fluorophotometry and tonography
data for these variables (Models 1a and 1b respectively). The same values for aqueous
flow and EVP were used for the two models. In the model with fluorophotometry data,
the change in IOP was significantly associated with aqueous flow and outflow facility.
Specifically, higher baseline aqueous flow was associated with a greater reduction in IOP
(p=0.004). Lower baseline outflow facility also was associated with greater reduction in
IOP (p=0.002).
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Similarly, in the model with tonographic data, both higher aqueous flow and lower
outflow facility were associated with a greater reduction in IOP. In addition, a lower
baseline uveoscleral outflow also was associated with a greater IOP reduction (p<0.001).
When percentage IOP reduction was used as the outcome variable there was no change
in substantive conclusions (data not presented).
In the patient demographics-based model (model 2), none of the variables were found
to be significantly associated with IOP response at an alpha of 0.05. However, a weak
association was seen between IOP response and age (p=0.052) and IOP response and
CCT (p=0.076). Specifically, the regression analysis approached significance for a greater
IOP response being associated with younger age and thinner corneas. None of the
treatment variables; angle pigmentation, percentage spots with visible bubbles or total
laser power were associated with IOP response (model 3, data not presented).

Discussion
Similar to ALT, the IOP lowering effect of SLT appears to be mediated through an
increase in outflow facility with no substantial effects on any of the other parameters of
AHD. Using Shiotz tonometry based tonographic assessment, other authors47,48 have
reported an increase in outflow facility after SLT. This study has an expanded design as
compared to any prior similar study. Both techniques used to assess outflow facility in
our study are different from the ones reported in the past. Episcleral venous pressure
and uveoscleral outflow calculations were included in the design to address all
parameters in the modified Goldmann equation. Contralateral eyes were also studied
for the first time and the negative results are important considering past speculations
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on the contralateral effects of SLT. The primarily Caucasian composition of our study
was different from any of the prior publications. The follow up measurement was done
at a consistent time after the laser allowing 3 months for laser effects to be established
prior to making repeat measurements. Given the fairly low baseline outflow facility in
the two prior reports (0.08 µl/min/mmHg and 0.09 µl/min/mmHg),47,48 our study
perhaps represents a more moderate degree of trabecular pathology, more
representative and generalizable to what is likely to be encountered in clinics.
In our study, as the criteria for IOP response was made more robust, the statistical
significance of increase in outflow facility became greater. Even though this is not a true
dose-response relationship, it does imply that for subjects with more IOP lowering,
increase in outflow facility was more obvious. At the same time there was no change in
outflow facility in subjects that did not have a good IOP response to SLT, adding
credence to the hypothesis that IOP changes after SLT are mediated through an increase
in outflow facility.
The overall magnitude of IOP response in our study subjects (approximately 15%) can
be considered to be modest compared to the expectation from SLT for primary therapy.
The mean clinic IOP, at which a decision was made to proceed with SLT was 26.05 ± 4.40
mmHg. This was considerably higher than the baseline visit’s IOP of 22.91 ± 5.12 mmHg
at 9 AM and 23.43 ± 4.60 mm Hg at 12 noon in the treated eye. The difference is
reflective of the regression to the mean that affects clinical glaucoma management,
where treatment decisions are typically made at IOP values on the higher end of the
tonometry measurement error or inherent diurnal IOP variability. This also highlights
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the potential overestimation of IOP response with the typical design of a retrospective
analysis where the most recent pretreatment IOP is considered the baseline IOP. The
modest IOP response seen in the study theoretically could be related to lower total
energy used for treatment as compared to some other studies of primary SLT.47,52 It can
be speculated that higher total energy levels could have affected additional parameters
of AHD besides outflow facility or may have shown greater changes in outflow facility.
However, we feel that the magnitude and particularly the range of responses seen in
the study served the purpose of the study well. We had a fair number of ‘nonresponders’ with either of the 2 criteria used to make such comparisons and multiple
regression analysis meaningful. Additionally, within the range of laser energy used in
this study, a correlation between the total laser energy used and IOP response was not
detectable. This study did not find any IOP or AHD effects in the contralateral untreated
eye. However, one prior study has raised the possibility of a crossover effect of laser
trabeculoplasty on the contralateral untreated eye.53
A direct comparison of baseline parameters between responders and non-responders
based on more robust criterion 2 (at least 10% IOP lowering at both measurement time
points) is presented in Table 3. Subjects with a greater response had a higher IOP at
baseline. Other than IOP, the difference between the parameters of AHD between the 2
groups was not significant. In other words, in such an arbitrary binary comparison, the
parameters of aqueous humor dynamics were not evidently predictive of treatment
response. IOP can be considered to be an outcome of the complex interplay between
parameters of AHD. Therefore, examining and contrasting these parameters between
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groups as covariates without controlling for others, is likely to yield limited information.
Multiple linear regression facilitates such evaluation of a covariate while controlling for
others in the model. Use of multiple regression revealed the significant influence of
baseline AHD parameters on IOP outcomes (Table 2).
Table 3: Comparison of baseline aqueous humor dynamics parameters in lasered eyes
with at least 10% IOP lowering at both 9 am and 12 noon to those that did not have
such a response.
Baseline Parameters

≥10% IOP
lowering(n=15)

< 10% IOP lowering
(n=14)

p*

IOP
(9 AM, mmHg)

25.38 ± 5.63

20.25 ± 2.77

0.005

IOP
(12 noon, mmHg)

25.61 ± 4.91

21.08 ± 2.85

0.006

Aqueous Flow
(µl/min)

2.82 ± 1.20

2.17 ± 0.92

0.11

Outflow Facility
(fluorophotometry, µl/min/mmHg)

0.16 ± 0.13

0.19 ± 0.09

0.60

Outflow Facility
(tonography, µl/min/mmHg)

0.15 ± 0.09

0.17 ± 0.07

0.52

Episcleral Venous Pressure
(mmHg)

9.91 ± 1.82

9.55 ± 0.98

0.53

Uveoscleral Outflow
(tonography, µl/min)

0.55 ± 1.64

0.18 ± 1.08

0.29

Uveoscleral Outflow
(fluorophotometry, µl/min)

0.61 ± 1.02

0.15 ± 0.85

0.46

*p-value using paired t-test
IOP=intraocular pressure

To the best of our knowledge, this is the first report using regression modelling
identifying what does and does not matter for laser response. This is perhaps the first
report to identify any pretreatment AHD predictors of response to any IOP lowering

27
treatment. Our study found a significant association between IOP response and AHD
parameters of aqueous flow rate and outflow facility. This association seen between
aqueous humor flow rate and IOP response for a fixed change in outflow facility is to be
expected based on Goldmann equation. Similarly, lower baseline outflow facility can
also expected to be more amenable to improvement after laser trabeculoplasty. The
results of multiple linear regression of the AHD data from this study experimentally
confirm these intuitive expectations. Based on the estimated coefficients in our
regression models we can speculate that for every 1 µl/min higher baseline aqueous
flow rate (approximately 40% higher than the study mean), the predicted IOP reduction
from SLT treatment was more by 2.38 ±0.75 mmHg (fluorophotometry based model) to
4.17 ± 0.97 mmHg (tonography based model). For every 0.1 µl/min/mmHg lower
baseline outflow facility, the predicted IOP reduction from SLT treatment was more by
2.68 ± 0.77 mmHg (fluorophotometry based model) to 5.15 ± 1.14 mmHg (tonography
based model). The application of this information to clinical care of patients currently is
limited by the techniques used to measure these variables. Aqueous flow determination
is a fairly time consuming exercise and difficult to incorporate into clinical practice.
Tonography has better potential as a clinical tool to predict treatment response prior to
laser treatment. However, the technique has substantial measurement noise, whereby
the repeatability at the individual level is low despite a very good reproducibility for
large sample means. Further advances in these techniques may allow for better
estimation of likelihood of individual treatment response and aid in patient selection
based on these baseline variables.
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This study did not find any statistically significant association between IOP response and
patient demographic variables or treatment variables possibly relevant to laser-tissue
interactions such as total laser energy, angle pigmentation or percentage of laser spots
with visible response. The association between younger age and greater IOP response
did approach statistical significance (β=-0.18, p=0.052). This translates into a possible
1.8 mm Hg (95% confidence interval of 0.0 to 3.6 mmHg) additional IOP response being
associated with a 10-year younger age of patient. The association with central corneal
thickness also approached statistical significance (β=0.04, p=0.076), implying a possible
additional 1.0 mm Hg (95% CI 0.0, 2.0) IOP response associated with 25 µ thinner
cornea. Thinner corneas have previously been shown to be associated with better IOP
lowering efficacy of topical medications.54 Even though the association between these
variables and IOP response did not reach statistical significance in this study, the authors
recommend controlling for these variables in future studies exploring the predictors of
response to laser trabeculoplasty.
Our study limitations are largely related to the limitations of the techniques available for
the assessment of AHD. Both fluorophotometry and tonography have several
assumptions that need to be taken into account when interpreting the data. The select
population required for the study such as exclusion of pseudophakic patients, and those
that could not be washed off meds safely, limits the generalizability of the results to
such subjects, who form a large part of any glaucoma practice.
Currently, the only way to assess uveoscleral outflow non-invasively is by mathematical
calculation. The result shows a fair amount of variability depending upon the EVP value
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used in the calculation.55 However, change in uveoscleral outflow is more robust to
errors in EVP estimation.56 Therefore, we have reported the changes in uveoscleral
outflow in this study, which is more meaningful than absolute values. A statistically
significant decrease in uveoscleral outflow was noted after SLT by the
fluorophotometric method but was not replicable with tonographic method. Therefore,
the strength of evidence to support any changes in uveoscleral outflow is weak. We
speculate that any small decrease in uveoscleral outflow after SLT, may merely reflect
more aqueous flowing through the trabecular than uveoscleral pathway. Proparacaine
drops were administered to measure the IOP and EVP in the same 7-hour period when
the fluorophotometry scans were obtained. These measurements can potentially
dislodge additional fluorescein and thereby result in an underestimation of the aqueous
flow rate. With the assumption that any systematic error will affect the two
measurement time points equally and thereby have negligible effect on the calculated
change in flow, we proceeded to obtain all IOP and EVP measurements on the same day,
to allow for chronologic proximity of all variables entered in the Goldmann equation.
In summary, this comprehensive study of changes in AHD three months after SLT found
the IOP lowering effects of SLT to be mediated through an increase in outflow facility.
No meaningful effects on any of the other parameters of AHD or the contralateral eye
were detected. A higher baseline aqueous flow and a lower baseline outflow facility
were found to be predictive of IOP response to SLT. Future advances in techniques for
the assessment of AHD may make these parameters useful for patient selection for
trabeculoplasty.
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Chapter Two: Differences in Ocular Biometrics and
Aqueous Humor Dynamics Between Chinese and Caucasian
Adults
In this paper, through collaborative work with investigators at Tenth People’s Hospital of
Tongji University, Shanghai Hospital aqueous humor dynamics were compared between
healthy young and older adult Chinese and Caucasian volunteers.57 The motivation
behind the research was to explore if there are systematic race-based differences in
biometrics and AHD between 2 populations known to have different profile for the
glaucoma sub type distribution. By enrolling 2 different age groups for each race group
the study also explores potential differences in age related changes in the 2 racial
groups.
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Abstract
Background: Glaucoma prevalence and subtype profile varies across different racial and
ethnic groups. This study provides a comparative evaluation of differences in aqueous
humor dynamics (AHD) and ocular biometrics in healthy Chinese and Caucasian adults of
2 different age groups.
Method: Data from two independent studies with identical designs were compared.
Cohorts included young adults (20 to 30 years old, 32 Chinese and 39 Caucasians) and
older adults (>50 years old, 37 Chinese and 46 Caucasians). Parameters of aqueous
humor dynamics and ocular biometrics were evaluated. Group comparisons were made
by generalized estimating equation methods.
Results: Differences in young adult Caucasians compared to similarly-aged Chinese were
thinner central cornea (-29.27µm, p<0.001); lower intraocular pressure (IOP) (-2.33
mmHg, p<0.001); larger anterior chamber volume (ACV) (28.78 µL, p<0.001) and faster
uveoscleral outflow rate (Fu) (0.82 µl/min, p<0.001). Differences in older adult
Caucasians compared to similarly-aged Chinese were slower aqueous flow rate (Fa) (0.28 µl/min, p=0.042); lower IOP (-1.97 mmHg, p<0.001); and larger ACV (33.15 µL,
p<0.001). Considering all subjects together by race, Caucasian subjects had slower Fa (0.22 µl/min, p=0.035); thinner corneas (-0.52 µm, p=0.003); lower IOP (-2.11 mmHg,
p<0.001); higher ACV (30.39 µl, p<0.001); and faster Fu (0.63 ul/min, p<0.001).
Conclusion: Differences in AHD and biometrics between Caucasian and Chinese adults
include larger anterior chamber volumes that may contribute to the wider angles
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reported in Caucasians; and slower aqueous flow rates coupled with faster uveoscleral
outflow rates that may contribute to their lower IOP and lower overall risk of glaucoma.
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Introduction
Race and ethnicity are significant determinants of the prevalence of different subtypes
of glaucoma in populations across the globe. Numerous studies have provided evidence
that primary open-angle glaucoma (POAG) is more common in people of European or
African descent while primary angle-closure glaucoma (PACG) is more prevalent in
Asians.28-30,58,59 Differences in ocular biometrics may underlie the differences in
glaucoma subtype profile between Caucasian and Asian adults. These differences in
ocular biometrics may translate into clinically relevant differences in variables of
aqueous humor dynamics (AHD). For example, ocular biometrics such as central cornea
thickness (CCT) may affect response to IOP lowering medications;60 and changes in
parameters of aqueous humor dynamics are associated with response to IOP lowering
treatments including drugs and procedures like laser trabeculoplasty.37 A study of
differences in biometric and AHD parameters in people across different ethnic
backgrounds can provide insights into the pathophysiology of glaucoma subtypes. It also
can help elucidate the mechanisms of variance in treatment response as it may relate to
these biometric and AHD differences. As IOP lowering, usually accomplished by altering
one or more parameters of AHD, remains the only available treatment for glaucoma,
exploring such differences across various racial and ethnic backgrounds is of clinical
value. This report is a comprehensive comparative evaluation of biometric and AHD
parameters between Caucasian and Chinese adults.
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Methods
The data in this study were compiled from two separate studies of the same design. The
studies were performed at the University of Nebraska Medical Center, Omaha, NE, USA
and Tenth People’s Hospital, Tongji University, Shanghai, China. During planning
meetings among the investigators, detailed study schedules were prepared and
standard operating procedures (SOPs) were written. Both centers followed the same
SOPs and schedules. To the extent possible, most of the equipment used in the two
institutions were of the same makes and models. Two groups of healthy volunteers
were enrolled at each site. The ‘young’ group included subjects 20 to 30 years of age,
and the ‘older’ group included subjects 50 years of age or older.
Subject demographics are summarized in Table 4. Those with a history or evidence of
ocular hypertension, glaucoma, uveitis, ocular trauma, intraocular or refractive surgery,
or ocular infection within the past 3 months were excluded from the study. Exclusion
criteria also included use of medications that affect aqueous humor production such as
β-adrenergic antagonists and/or carbonic anhydrase inhibitors, history of
hypersensitivity to fluorescein, abnormalities preventing reliable IOP or
fluorophotometric readings; such as severe dry eye, and serious cardiovascular or
respiratory diseases. The young groups included 32 Chinese and 39 Caucasian adults,
and the older groups included 37 Chinese and 46 Caucasian adults. Eligible subjects
underwent a comprehensive ocular examination including gonioscopy and fundus
examination. Study approval was obtained from the research ethics committees at the
University of Nebraska Medical Center and the Tenth People’s Hospital of Tongji
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University. Written informed consent was obtained from each volunteer before the
start of any study-related activity.
Table 4: Baseline Demographic Characteristics of Chinese and Caucasian study subjects
Chinese

Caucasian

Demographics

Young

Old

Young

Old

Mean age (years ± SD)

22.8±1.4

60.2±7.3

25.8±2.1

66.8±5.2

Age range (years)

20 – 28

50 – 78

21– 30

50 – 79

Male

13

8

16

15

Female

19

29

23

31

Total subjects enrolled

32

37

39

46

Number of subjects
taking systemic
medications

0

8*

4*

9*

* 21 Subjects were taking non-ophthalmic systemic medications such as birth control pills;
calcium channel blockers and angiotensin-II receptor antagonists for systemic hypertension,
proton pump inhibitors, sulfonylurea for type II diabetes mellitus and warfarin for anticoagulation.

Measurements
Volunteers self-administered 8 to 10 drops of 2% fluorescein sodium ophthalmic
solution topically into both eyes at 5-minute intervals starting at six to nine hours before
the first fluorophotometric measurement. The number of drops and time of
administration depended on the subject’s age.61 Study related measurements
commenced at approximately 8AM the following morning. CCT was measured by
ultrasound pachymetry (A-Scan ultrasonography (Pacscan Series 300, Sonomed, Lake
Success, NY at UNMC and SP-3000, Tomy, Japan at Tenth People’s Hospital). Anterior
chamber depth (ACd) was measured by Pacscan (Series 300; Sonomed, Lake Success,
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NY) at UNMC and by IOL Master 500 (Carl Zeiss Meditec Inc., Dublin, CA) at Tenth
People’s Hospital. ACd and CCT were used to calculate the anterior chamber volume
(ACV) and cornea volume (Kv).62 Both volumes were used in the calculation of aqueous
flow.63 At both sites, IOP was measured with a pneumatonometer (Classic Model 30,
Reichert, Depew, NY) and episcleral venous pressure (EVP) was measured with a
venomanometer (Eyetech, Morton Grove, IL).49 The reported values are the average of
two or three measurements per eye.
Four sets of duplicate fluorophotometric scans of the cornea and anterior chamber at
intervals of 45 minutes were collected using a scanning ocular fluorophotometer
(Fluorotron Master; OcuMetrics, Mountain View, CA, USA) at both sites. The slope
calculated from four averaged values was used to obtain a baseline flow rate of aqueous
humor. IOPs were measured immediately after the first and fourth sets of
fluorophotometer scans. Next, topical timolol 0.5% was applied to both eyes or oral
acetazolamide (500 mg) was given to the subjects. These drugs are known to decrease
the IOP by decreasing aqueous production.62,64,65 One hour after the administration of
the aqueous humor suppressants, three additional sets of fluorescein scans and IOP
measurements were obtained at 45 min intervals to allow calculation of
fluorophotometric outflow facility (C) as the quotient of change in aqueous flow divided
by change in IOP.66,67 Uveoscleral outflow (Fu) was calculated42,66 from the modified
Goldmann equation.
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Sample size and Power
Computed were the minimum detectable differences between Caucasian and Chinese
subjects for different major outcomes stratified by age groups. Intraclass correlation
coefficient (ICC) was used to account for the clustering effect between the two eyes
from the same individual. From the data were obtained ICC values of 0.65 for the young
group and 0.28 for the old group, and standard deviations for different major outcomes.
Based on the adjusted two-sample t test, the sample size of 32 for each young group (64
total) achieves 80% power to detect a minimum IOP difference of 0.97 mmHg between
Caucasian and Chinese subjects with a significance level of 0.05. The sample size (39
Caucasian and 32 Chinese) provided more than 80% power to detect such a difference.
The minimum detectable differences in other variables at an alpha of 0.05 and a power
of 80% are presented in Table 5.
Table 5: The minimum detectable difference for different major outcomes for the young
and older groups at an alpha of 0.05 with 80% power.

Outcomes
Intraocular pressure
(IOP mmHg)
Aqueous flow
(Fa µl/min)
Uveoscleral outflow
(Fu µl/min)
Fluorophotometric C
(C µl/min/mmHg)
Episcleral venous pressure
(EVP mmHg)
Central corneal thickness
(CCT µm)

Young (N=32)
Minimum
Standard
Detectable
Deviation
Difference

Older adults (N=36)
Minimum
Standard
Detectable
Deviation
Difference

1.500

0.969

2.100

1.125

0.700

0.452

0.800

0.429

1.000

0.646

1.000

0.536

0.300

0.194

0.300

0.161

1.100

0.711

1.200

0.643

27.100

17.513

36.100

19.337
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Statistical Analyses
For all major outcomes and covariates, descriptive statistics such as mean, standard
deviation, frequency and percentage were calculated for Chinese and Caucasian adults
stratified by age groups (young and older adults, Table 6). For these tests, the
correlations between the two eyes were ignored. Generalized estimating equation (GEE)
methods with identity link for continuous data were used to incorporate the correlation
of two eyes from the same individual and to account for other potential confounders
(such as sex). To test for heterogeneous effects of race in difference age groups, an
interaction between race and age group was added into the model. P values less than
0.05 were considered statistically significant. All analyses were conducted using SAS
(version 9.4).
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Table 6: Descriptive statistics for biometric and aqueous humor dynamics variables in different age and race groups

Young Adults
Caucasian

Older Adults

Chinese

Caucasian

All Subjects

Chinese

Caucasian

Chinese

Variable

N

Mean±SD

N

Mean±SD

N

Mean±SD

N

Mean±SD

N

Mean±SD

N

Mean±SD

IOP

78

14.06±2.46

64

16.40±1.53

92

14.48±2.68

73

16.49±2.10

170

14.29±2.58

137

16.45±1.85

Fa

78

2.89±0.84

63

3.03±0.74

92

2.42±0.70

73

2.68±0.78

170

2.63±0.80

136

2.85±0.78

Fu

76

1.51±0.92

55

0.98±1.13

91

1.03±0.91

62

0.74±0.99

167

1.25±0.94

117

0.85±1.06

C

76

0.25±0.13

55

0.31±0.13

91

0.29±0.18

62

0.32±0.25

167

0.27±0.16

117

0.33±0.29

EVP

78

8.66±1.75

63

8.51±1.14

92

8.90±1.82

73

8.63±1.16

170

8.79±1.78

136

8.57±1.15

ACV

78

244.8±41.7

64

215.9±31.0

92

161.2±39.3

73

129.2±33.5

170

196.6±58.0

137

169.7±54.0

CCT

78

520.4±35.8

64

549.7±27.0

92

532.1±29.6

73

530.9±36.0

170

526.8±33.3

137

539.7±33.4

ACV, anterior chamber volume; C, outflow facility; CCT, central corneal thickness; Fa, aqueous flow; Fu, uveoscleral outflow; IOP, intraocular pressure;
EVP, episcleral venous pressure; Data are represented as mean ± SD.
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Results
When comparing young Caucasian with Chinese adults, IOP was lower (adjusted effect=2.33 mmHg, p<0.001), Fu was higher (adjusted effect=0.82 µl/min, p<0.001), CCT was
thinner (adjusted effect=-29.27µm, p<0.001) and ACV was larger (adjusted effect=28.78
µl, p<0.001) in Caucasian subjects. No difference was found in EVP (adjusted effect=0.17
mmHg, p=0.582), Fa (adjusted effect= -0.14 µl/min, p=0.367) and C (adjusted effect=0.09µl/min/mmHg, p=0.057).
When comparing older Caucasian with Chinese adults, IOP was lower (adjusted effect=1.97 mmHg, p<0.001), Fa was higher (adjusted effect=-0.28 µl/min, p=0.042), Fu was
higher (adjusted effect=0. 60 µl/min, p=0.004) and ACV was higher (adjusted
effect=33.15, p<0.001) in Caucasian subjects. No difference was found in EVP (adjusted
effect=0.25 mmHg, p=0.4), C (adjusted effect=-0.03 µl/min/mmHg, p=0.4) and CCT
(adjusted effect=1.26 µm, p=0.96).
When combining all data within racial groups and comparing Caucasians with Chinese,
IOP was lower (adjusted effect=-2.11 mmHg, p<0.001), Fa was lower (adjusted effect=0.22 µl/min, p=0.035); Fu was higher (adjusted effect=0.63 µl/min, p<0.001), CCT was
thinner (adjusted effect=-30.5 µm, p=0.003) and ACV was higher (adjusted effect=30.4
µl, p<0.001). A lower outflow facility in the Caucasian group (adjusted effect=-0.06
µl/min/mmHg, p=0.05) approached statistical significance. No difference was found in
EVP (adjusted effect=0.21 mmHg, p=0.304) between the 2 racial groups. These results
are summarized in Table 7.

41

Table 7: The effect of race on different continuous outcomes based on GEE, controlled for gender. Values are presented as mean
expected difference for Caucasian minus Chinese.

Young

Old

Overall

Outcomes

Adjusted Effect
(95% CI)

Adjusted
p-value*

Adjusted Effect
(95% CI)

Adjusted
p-value*

Adjusted Effect (95%
CI)

Adjusted
p-value*

IOP

-2.33 (-3.19, -1.48)

<0.001

-1.97 (-2.97, -0.96)

<0.001

-2.11 (-2.78, -1.44)

<0.001

Fa

-0.14 (-0.46, 0.17)

0.367

-0.28 (-0.54, -0.01)

0.042

-0.22 (-0.43, -0.02)

0.035

Fu

0.82 (0.45, 1.19)

<0.001

0.60 (0.20, 1.0)

0.004

0.63 (0.37, 0.90)

<0.001

C

-0.09 (-0.19, 0.0003)

0.057

-0.03 (-0.10, 0.04)

0.398

-0.06 (-0.12, 0.0004)

0.050

EVP

0.17 (-0.42, 0.76)

0.582

0.25 (-0.33, 0.83)

0.399

0.21 (-0.20, 0.62)

0.304

ACV

28.78 (13.40, 44.16)

<0.001

33.15 (18.01, 48.30)

<0.001

30.39 (18.89, 41.29)

<0.001

CCT

-29.27 (-43.29, -15.25)

<0.001

1.26 (-12.97, 15.50)

0.962

-30.52 (-50.50, -10.55)

0.003

*p-values represent the adjusted p value comparing Race and controlling for sex.
ACV, anterior chamber volume, μL; C, outflow facility, μL/min/mm Hg; CCT, central corneal thickness, μm; Fa, aqueous flow, μL/min; Fu, uveoscleral
outflow, μL/min; IOP, intraocular pressure, mm Hg; EVP, episcleral venous pressure, mm Hg.
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Discussion
This study describes numerous differences in aqueous humor dynamics and ocular
biometrics between Chinese and Caucasian adults; differences that demonstrate
additional change with aging. Independent of age, the main findings were that anterior
chamber volume was larger and uveoscleral outflow was higher in Caucasian adults
which may explain, at least in part, the lower IOP in Caucasian compared to Chinese
adults.
A finding of interest in the current study is the apparent association between the
volume of the anterior chamber and the drainage through the uvea. A putative point of
egress of aqueous humor from the anterior chamber is at the ciliary body face which is
devoid of any epithelial barrier. A wider ciliary body band may be associated with larger
anterior chamber and may represent a larger area with access to aqueous humor. On a
univariate analysis with the GEE model, anterior chamber volume was significantly
associated with uveoscleral outflow (p=0.0004), implying that a faster uveoscleral
outflow rate is indeed associated with a deeper anterior chamber. A narrowing of the
anterior chamber angle may decrease the drainage through the uvea causing an IOP
rise, thus providing a potential explanation for the higher prevalence of glaucoma in
Asian populations.
One notable difference in the speculated effects of aging on AHD parameters between
Chinese and Caucasians was the age-related slowing of aqueous humor flow. It was
slower in older Caucasians compared to older Chinese, a difference that was not found
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among the young groups. This may imply a greater age-related decline in aqueous
humor production in Caucasians as compared to Chinese subjects.
One noteworthy difference in the speculated effects of aging on ocular biometrics was
that CCT was thinner in young but not older Caucasians compared to Chinese. CCT is
genetically heritable and varies among racial groups.68-73 The distribution of CCT in the
current study is similar to a multi-race population-based study, which showed that
Chinese adults had significantly thicker CCT compared with the other racial groups.68 In
the current study, CCT increased with aging in Caucasians yet decreased with aging with
Chinese. This agrees with previous studies.74 69,75 Assuming there are no cohort effects
due to the convenience sample used in our study, our findings may corroborate
divergent effects of aging on CCT in Caucasian and Chinese subjects.
Differences in ocular biometric parameters may contribute to racial differences in
glaucoma risk, particularly for primary angle-closure glaucoma (PACG), which is found
with highest prevalence in Asians.76 Anterior chamber depth is an inheritable trait which
is affected by age, sex and race.77 Shallower anterior chambers and shorter axial lengths
are risk factors for PACG.78,79 In the present study, Chinese adults have smaller ACV
compared with Caucasian adults possibly from a thinner ciliary body and a more
anteriorly positioned lens,80 findings consistent with the differential risk for angle
closure among Asians and Caucasians.
The current study showed that outflow facility is not significantly different between
Caucasians and Chinese. When the racial groups were separated by age, both young and
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older adult groups had a numerically smaller average C in Caucasians, but the
differences were only marginally significant in young adults and not significant in older
adults. No differences in outflow facility were found in a study comparing patients with
glaucoma of Northern European and African descent.81
Trabecular outflow is driven by the outflow pressure (the difference between the IOP
and EVP). The assessment and understanding of EVP are essential for a more complete
picture of aqueous humor dynamics. The current study did not show significant
differences in the EVP between Chinese and Caucasian adults but did find lower IOP in
Caucasians. Hence, in Chinese, the outflow pressure and trabecular outflow rate are
greater and the uveoscleral outflow pathway plays a lesser role in the drainage of
aqueous humor compared to Caucasians.
Our study subjects were selected as a convenience sample from two very different
health care systems. Despite meticulous attention to inclusion and exclusion criteria, the
possibility of inherent systematic differences in the pool of subjects available for
enrollment may exist. The potential for cohort effects being responsible for the
differences seen in this study cannot be absolutely ruled out. Given the poor feasibility
of random population-based sampling for the time and effort intensive data collection
methods needed for AHD studies, such limitations are difficult to circumvent. Agerelated changes in any parameter are perhaps best addressed using a longitudinal
design. Even though feasible for some animal models, cross-sectional studies, such as
this one, are the most feasible option when evaluating changes across the decades in
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humans. Despite these limitations this study provides insights into race-based
differences in AHD parameters and the effects of aging on the same.
A comparison of sex differences between the races found that differences were similar
in males and females. However, significant differences were not reached in males
because the study was neither designed nor powered to detect gender-based
differences by race. These data may be misconstrued as lack of statistical significance
rather than lack of power to detect sex differences. Therefore, the data are not
reported. A future study with larger numbers and targeted enrollment of equal numbers
of males and females can better address this issue.
Every effort was made to collect data at each research center with the same make and
model of equipment. This was not possible for the measurement of anterior chamber
depth. In Caucasians this parameter was measured with A-scan while in Chinese it was
measured with an IOL Master. One published study82 has reported that the measured
AC depth from the two instruments are highly correlated. Other studies83-85 found that
the A-scan gives lower measurements than the IOL Master. The difference in anterior
chamber depth between Chinese and Caucasians in the current study may be greater
than reported here with greater statistical significance. Our conclusions regarding racial
differences in AC depth remain valid.
In summary, differences exist in anterior chamber volume, IOP, aqueous flow and
uveoscleral outflow between Caucasian and Chinese subjects. This study also provides
limited initial evidence on possible differential effects of aging on CCT and aqueous flow
in Caucasian and Chinese subjects. These results, with further validation and support,
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may help explain differences in pathophysiology and prevalence of glaucoma in people
of different racial backgrounds. These parameters also may have future application as
target biomarkers for glaucoma diagnostics and therapeutics.
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Chapter Three: Predictors of Intraocular Pressure Lowering
after Phacoemulsification and iStent® Implantation
Traditional glaucoma surgery such as trabeculectomy and glaucoma drainage devices
are associated with high rates of surgical complications.86 There has been extensive
interest of late in trabecular bypass implants such as iStent and Hydrus implants, as a
potential lower risk option for IOP lowering. However, the IOP lowering success rate for
these devices has been somewhat underwhelming. This paper evaluates the clinical and
demographic factors associated with surgical success of iStent, the first trabecular
bypass stent approved by the FDA, to be used in conjunction with cataract surgery. The
study also explores factors associated with IOP lowering success of cataract surgery
alone, where the addition of iStent to the procedure may not add much to the surgical
success.
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Abstract
Objective: To explore the demographic and clinical variables associated with intraocular
pressure lowering after cataract extraction alone (CE) or in combination with iStent
placement (CE-IS).
Design: Retrospective data extraction and survival analysis of consecutive patients
identified over a 2-year period.
Subjects: Patients with mild to moderate glaucoma who underwent CE (48 eyes from 32
patients) or CE-IS (61 eyes from 37 patients) were analyzed.
Methods: Inability to reduce the number of medications or the IOP by at least 20%
compared to baseline on 2 consecutive visits was considered surgical failure. Using Cox
proportional hazards models, survival analysis was performed, and demographic and
clinical variables were evaluated as risk factors.
Main Outcome Measures: Time to failure after surgical procedure.
Results: CE-IS had lower odds of failure than CE (HR=2.01, p=0.047). In Caucasian
subjects, CE-IS had greater odds of success as compared to CE alone (HR=2.86, p=0.007).
For non-Caucasian subjects there was no difference in the outcomes for the 2
procedures (HR 0.59, p=0.48). In the multivariate analysis, non-Caucasian race (HR=8.75,
p=0.0002) and longer axial length (HR=1.61, p=0.03) were associated with greater
hazard of failure after CE-IS. In the CE group, greater odds of failure were associated
with steeper corneal curvature (HR=1.74, p=0.008), shallower anterior chamber
(HR=0.22, p=0.008), and longer axial length (HR=1.58, p=0.01).
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Conclusions: Addition of iStent to CE improved the survival of IOP lowering success in
Caucasians but not in non-Caucasians. Associations between IOP lowering after CE and
biometric parameters may allow for leveraging these clinical parameters for better case
selection for these procedures.
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Introduction
Intraocular pressure (IOP) remains the strongest risk factor for development and
progression of glaucomatous visual field loss. The management of glaucoma relies
heavily on sustained reduction of IOP.87 Topical ocular hypotensive medications or laser
trabeculoplasty are typically considered first-line therapies for IOP lowering. In patients
with inadequately controlled IOP, trabeculectomy or ab externo valve placement is
considered. However, these procedures are associated with a high incidence of short
and long-term complications, including infection, hypotony, scarring, and need for
further surgeries.86 Trabecular bypass and scaffolding implants that are typically placed
at the time of cataract surgery constitute some of the minimally invasive glaucoma
surgeries (MIGS), intended to avoid the complications associated with traditional
aqueous shunting procedures. In 2012, the iStent implant (Glaukos Corporation, CA,
USA) became the first FDA-approved ab interno device to be used for IOP lowering in
combination with cataract extraction. Compared to cataract extraction alone, the
addition of iStent improved IOP lowering or reduced the number of glaucoma
medications in mild to moderate glaucoma patients.34
Since the introduction of the iStent, several studies have described its limitations, such
as the surgical complexity of implantation, its need to be combined with cataract
surgery, and its inability to lower IOP as well as ab externo procedures.34,88-90 As a result,
the lower rate of surgical complications is offset by lower efficacy in IOP lowering with
MIGS procedures. To be able to identify the patient characteristics most likely to have
an IOP lowering benefit from cataract extraction either with or without MIGS will have
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significant value in guiding patient selection for these procedures. Even though the risk
factors for failure such as race and prior procedures are relatively well known for
conventional glaucoma procedures, these have not been well characterized for MIGS
procedures. Additionally, ab interno trabecular bypass glaucoma procedures, in theory,
should be able to minimize the perils of conjunctival scarring seen in conventional
glaucoma surgeries.
This study investigates the success in IOP lowering and medication reduction with
cataract extraction with or without iStent implantation in mild to moderate glaucoma
patients in an academic practice. With an exploratory analysis, clinical covariates were
identified that were predictive of IOP lowering success with either of the 2 procedures
evaluated.

Methods

This retrospective cohort study was approved by the University of Nebraska Medical
Center Institutional Review Board. Subjects with a diagnosis of ocular hypertension or
mild to moderate glaucoma who underwent cataract surgery with iStent implantation
(CE-IS) or cataract surgery alone (CE) from 2015-2017 at the University of Nebraska
Medical Center were included in this study. In patients with surgery performed on both
eyes, each eye was included in the study.
All available IOP data from up to one year prior to the surgical procedure to the last
available follow up visit were extracted from patient records. If more than one IOP was
recorded on a given day, the one recorded by the attending or resident physician was
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included for analysis. All IOPs were recorded using either Goldmann applanation
tonometry or pneumatonometry, though the method varied for the same patient from
visit to visit. Number of topical IOP lowering medications being used at each of these
visits was also recorded. Combination glaucoma medications were recorded as two
medications. Oral acetazolamide or methazolamide use was also counted in the study as
a single glaucoma medication. Demographic data including age, sex, and race/ethnicity
were recorded. Known history of prior laser trabeculoplasty and biometric data
including keratometry, anterior chamber depth, and axial length were collected as well.
Systemic comorbidities of hypertension, hyperlipidemia, and diabetes were recorded
from the patient problem list available in the electronic medical records. Operative and
clinic notes were reviewed to confirm the procedure performed (cataract surgery alone
or combined with iStent).
The average of all available IOPs up to one year prior to the surgical procedure was
considered the baseline IOP for that individual, and the median number of medications
in that period was used as the baseline number of medications. Eyes were evaluated for
failure on all visits after the first 30 days post operatively. This was done to allow for
resolution of any transient post-operative hyphema and effects of post-operative
steroids, as these would be considered the normal post-operative course for these
procedures. At each clinic visit after 30 days, IOP change was calculated as percentage
change from baseline and medication change was noted as numerical change from
baseline number of medications. Surgical failure was defined as inability to lower the
number of medications from baseline or reduce the IOP by at least 20% compared to
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baseline on two consecutive visits. If the failure criteria were met on the last available
visit with no subsequent visit for confirmation, the eye was categorized as a surgical
failure. When the failure criteria were met on two consecutive visits, time to failure was
recorded as that of the first of these visits. Subjects who had less than 30 days of postoperative follow-up (minimum required period to be at risk for failure) were excluded
from the analysis.
Primary data analysis was done using survival analysis methods with time to failure
being the primary outcome variable. Primary comparator groups were based on the
surgical procedure performed, namely cataract surgery with or without iStent. Effect of
covariates on surgical success was analyzed separately for each group. SAS version 9.4
(Cary, NC) was used for all data analysis. A p value less than 0.05 was considered
statistically significant. Descriptive analysis was performed on all variables. Summary
measures including mean, standard deviation, and quartiles were obtained for all
continuous variables. Frequency distributions were obtained for all categorical variables.
In this report, IOP and medication use data over time are presented as spaghetti plots of
individual subjects with a mean overlay plot using a fitted smoothed line using a spline
routine. Univariate effects of variables on time to failure was studied using Kaplan Meier
curves and log rank test and hazard ratios estimated using Cox proportional hazards
(PH) model. Quartiles of continuous variables and categories of categorical variables
were used for generating the Kaplan Meier curves. Quartile conversion of continuous
variables was not required for the Cox PH model. Variables with p value less than 0.05
on univariate analysis and those considered to be clinically relevant confounders on
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secondary analysis were entered in the multivariate analysis. To account for the effect
of inclusion of both eyes of some of the subjects in the analysis, robust sandwich
estimate of Lin and Wei was used for the covariance matrix (using COVS(AGGREGATE)
option in PHREG procedure in SAS).91

Results
A total of 64 eyes (39 subjects) undergoing CE-IS were initially identified for inclusion in
the study. Three eyes (2 subjects) were excluded because of inadequate follow up (less
than 30 days after surgery). In the CE group 65 eyes (44 subjects) were initially identified
for inclusion in the study. Upon a further detailed review of the chart, 17 eyes of 12
subjects were excluded for the reasons as follows. In 3 eyes (3 subjects) iStent
implantation was attempted after CE but was unsuccessful. In 4 eyes (3 subjects), there
was history of past laser iridotomy with persistent angle closure, one due to peripheral
anterior synechiae and 3 due to plateau iris configuration. Another 4 eyes (3 subjects)
had a history of prior laser iridotomy with gonioscopy not available in the
documentation. Of these 3 subjects, one (2 excluded eyes) was also using systemic
prednisolone and another (one excluded eye) had proliferative diabetic retinopathy
documented in the chart. Two subjects (4 eyes) were excluded as they had newly
diagnosed narrow angles with iridotomy deferred due to planned cataract surgery. Two
eyes (one subject) with a history of anterior uveitis and peripheral anterior synechiae on
gonioscopy were also excluded from analysis. For the analysis presented in this report,
61 eyes from 37 patients were included in the CE-IS group, and 48 eyes from 32 patients
were included in the CE group. Among the analyzed subjects, systemic comorbidities
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data and biometry data was not available for one subject each in CE-IS group. Anterior
chamber depth data was not available for 2 additional subjects in the CE group.
A comparison of the baseline demographic and clinical characteristics of the 2 study
groups is presented in Table 8. There was no significant difference in age, sex, race or
ethnicity, preoperative IOP, or number of medications between the 2 study groups. A
higher proportion of CE-IS eyes had a history of prior laser trabeculoplasty.
Table 8: Baseline demographic and clinical characteristics of the study population
CE-IS
61 eyes (37 patients)

CE
48 eyes (32 patients)

*p
value

Age (years)

71.0 ± 8.1

74.2 ± 7.2

0.09

Male sex % (n)

29.7% (11)

43.8% (14)

0.32

Caucasian race % (n)

86.5% (32)

71.9% (23)

0.15

Pre-operative IOP (mm Hg)

17.26 ± 3.1

17.64 ± 2.3

0.48

Pre-operative # of medications

1.5 ± 1.1

1.2 ± 1.1

0.22

Prior laser trabeculoplasty % (n)

31.1% (19)

8.3% (4)

0.004

Diabetes % (n)

19.4% (7)

18.8% (6)

0.99

Hypertension % (n)

55.5% (20)

75.0% (24)

0.13

Hyperlipidemia % (n)

38.9% (14)

43.8% (14)

0.81

* p value obtained using Student’s t-test for continuous variables and Fisher’s exact test for
categorical variables. Data on systemic comorbidities was not available for one subject in the CEIS group.
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Figure 4 shows the IOP and medication trend over time for all individual subjects and
the overall trend for the same in the 2 study groups over time. Overall, there was a 2-3
mmHg reduction in IOP over the first year as compared to the IOP in the year preceding
the surgery. There was approximately 1 less medication used in the first year after the
procedure in both study groups.
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Figure 4: Trends in intraocular pressure and number of medications over time in the CE-IS and CE groups. The plots show individual
cases (light blue) with the trendline (dark blue) for overall trend generated using a smoothed curve with spline routine
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Kaplan Meier survival curves for the CE and CE-IS groups are shown in Figure 5. Patients
undergoing CE-IS had lower odds of failure as compared to patients in the CE group (HR
2.01, p=0.047).
Figure 5: Kaplan-Meier survival curves with 95% confidence interval comparing surgical
success among all patients between cataract surgery with iStent and cataract surgery
without iStent. Univariate Cox proportional hazard model based hazard ratio was 2.01
(CI 1.01-4.01, p=0.047).

CE=cataract extraction; CE-IS = cataract extraction with Istent. Numbers above X axis indicates
number of eyes at risk at each time point.

Univariate Cox proportional hazards model analysis of risk factors for failure in the CE-IS
group is displayed in Table 9. A greater hazard of failure was associated with nonCaucasian race (HR 3.65, p=0.01) and lower number of pre-operative medications (HR
0.58, p=0.03).
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Table 9: Univariate and multivariate Cox proportional hazards model analysis of risk
factors in patients undergoing cataract surgery with iStent
Univariate

Multivariate

Hazard
Ratio

Confidence
interval

p
value

Hazard
Ratio

Confidence
interval

p value

Age (1 year)

0.99

0.92-1.07

0.88

1.04

0.98-1.10

0.22

Sex (female)

1.60

0.60-4.27

0.35

Race (Caucasian)

3.65

1.29-10.33

0.01

8.75

2.80-27.31

0.0002

Pre-operative IOP (1 mmHg)

1.09

0.95-1.26

0.22

1.06

0.88-1.29

0.52

Pre-operative # of medications
(1 medication)

0.58

0.36-0.95

0.03

0.63

0.33-1.21

0.16

Selective laser trabeculoplasty

0.40

0.13-1.21

0.10

Corneal curvature (1 diopter)

0.86

0.68-1.09

0.22

Axial length (1 mm)

1.29

0.93-1.78

0.13

1.61

1.05-2.47

0.03

Anterior chamber depth (1
mm)

1.53

0.52-4.53

0.45

Hypertension

1.44

0.45-4.63

0.54

Diabetes

1.77

0.60-5.27

0.30

Hyperlipidemia

1.37

0.48-3.96

0.56

Variable (reference)

A comparison of Kaplan-Meier curves demonstrating the surgical success of CE-IS
between Caucasian and non-Caucasian subjects is presented in Figure 6.
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Figure 6: Kaplan-Meier survival curves with 95% confidence intervals comparing success
of cataract surgery with iStent implantation between Caucasians and non-Caucasians.
Univariate Cox proportional hazard model based hazard ratio was 3.65 (CI 1.29-10.33,
p=0.01)

Numbers above X axis indicates number of eyes at risk at each time point.

To evaluate for systematic differences between the Caucasian and non-Caucasian
population, baseline demographic and clinical variables were compared between the
two groups (Table 10). Caucasians subjects had lower pre-operative IOP (16.9 ± 3.2 vs
19.0 ± 1.7, p=0.009). Nearing significance were older age (71.9 ± 7.4 vs 65.7 ± 11.2 years,
p=0.07) and longer axial length (25.0 ± 1.6 vs 23.9 ± 1.4 mm, p=0.07) in the Caucasian
subjects. No other variable was different between the 2 groups. Variables entered in the
multivariate analysis were those that were statistically significant in the univariate
analysis and others that needed to be controlled for because of possible different
distributions in the 2 race-based groups.
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Table 10: Comparison of demographic and biometric variables between Caucasian and
non-Caucasian subjects in the CE-IS group.
Caucasians
51 eyes (32 subjects)

Non-Caucasians
10 eyes (5 subjects)

p value*

Age (years)

71.9 ± 7.4

65.7 ± 11.2

0.07

Corneal curvature (D)

43.7 ± 1.8

43.9 ± 1.5

0.72

Axial length (mm)

25.0 ± 1.6

23.9 ± 1.6

0.07

Anterior chamber depth (mm)

3.23 ± 0.4

3.11 ± 0.6

0.72

Pre-operative # of
medications

1.6 ± 1.2

1.2 ± 0.7

0.43

Pre-operative IOP (mm Hg)

16.9 ± 3.2

19.0 ± 1.7

0.009

* p values calculated using Mann-Whitney test

In the multivariate analysis, non-Caucasian race was associated with increased odds of
surgical failure compared with Caucasians (HR 8.75, p=0.0002). A greater axial length
was also associated with higher risk of surgical failure (HR 1.61, p=0.03) after controlling
for other variables in the model. Results of multivariate analysis in the CE-IS group are
included in Table 9.
Univariate Cox proportional hazards model analysis of patients in the CE group (Table
11) found a greater hazard of failure associated with lower pre-operative IOP (HR 0.81,
p=0.04), steeper corneal curvature (HR 1.42, p=0.03), shallower anterior chamber depth
(HR 0.28, p=0.01), and presence of systemic hypertension (p=0.008). No failure events
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were encountered in the non-hypertensive group. This precluded calculation of a hazard
ratio based on application of the proportional hazards model to this variable. Therefore,
log rank test was used to determine statistical significance of effect of hypertension on
the survival curves, and the variable was not used in the multivariate model.
Table 11: Univariate and multivariate Cox proportional hazards model analysis of risk
factors for failure in patients undergoing cataract surgery alone
Univariate model

Multivariate model

Hazard
Ratio

Confidence
interval

p
value

Hazard
Ratio

Confidence
interval

p
value

Age (1 year)

0.98

0.92-1.04

0.48

Sex (female)

1.35

0.52-3.47

0.54

Race (Caucasian)

0.91

0.22-3.67

0.89

0.50

0.13-1.91

0.31

Pre-operative IOP (1 mmHg)

0.81

0.65-1.00

0.04

0.87

0.74-1.02

0.09

Pre-operative # of medications
(1 medication)

0.55

0.24-1.26

0.15

Selective laser trabeculoplasty

0.81

0.30-2.16

0.68

Keratometry (1 diopter)

1.42

1.03-1.95

0.03

1.74

1.15-2.62

0.008

Axial length (1 mm)

0.98

0.73-1.30

0.88

1.58

1.10-2.29

0.01

Anterior chamber depth (1
mm)

0.28

0.11-0.74

0.01

0.22

0.07-0.68

0.008

-

-

0.008

Diabetes

0.68

0.21-2.20

0.52

Hyperlipidemia

1.32

0.55-3.15

0.53

Variable (reference)

Hypertension*
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In the multivariate model (Table 11), greater hazard of failure was associated with a
longer axial length (HR=1.58, p=0.01), steeper corneal curvature (HR=1.74, p=0.008) and
shallower anterior chamber (HR=0.22, p=0.008). There was no difference in survival of
surgical success between Caucasian and non-Caucasian subjects in the CE group. A
Kaplan-Meier curve demonstrating comparable CE surgical success between Caucasians
and non-Caucasians is shown in Figure 7.
Figure 7: Kaplan-Meier survival curves with 95% confidence intervals comparing IOP
lowering success of cataract surgery between Caucasians and non-Caucasians.
Univariate Cox proportional hazard model based hazard ratio was 0.91 (CI 0.22-3.67,
p=0.89).

Numbers above X axis indicates number of eyes at risk at each time point.

Surgical success for the 2 procedures was compared separately in the 2 race groups.
Kaplan-Meier curves comparing surgical success of CE-IS and CE among Caucasians is
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shown in Figure 8. Patients in the CE-IS group were more likely to maintain surgical
success compared to CE alone (HR 2.86, CI 1.33-6.14, p=0.007).
Figure 8: Kaplan-Meier survival curves with 95% confidence intervals comparing IOP
lowering success of CE and CE-IS in Caucasian subjects only. Univariate Cox proportional
hazard model based hazard ratio was 2.86 (CI 1.33-6.14, p=0.007).

CE=cataract extraction; CE-IS = cataract extraction with Istent
Numbers above X axis indicates number of eyes at risk at each time point.

Surgical success for the 2 procedures among non-Caucasians is shown in Figure 9. There
was no difference between the survival curves for CE-IS and CE in this group (HR 0.59, CI
0.13-2.54, p=0.48).
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Figure 9: Kaplan-Meier survival curves with 95% confidence intervals comparing IOP
lowering success of CE and CE-IS in non-Caucasian subjects only. Univariate Cox
proportional hazard model based hazard ratio was 0.59 (CI 0.13-2.54, p=0.48).

CE=cataract extraction; CE-IS = cataract extraction with Istent
Numbers above X axis indicates number of eyes at risk at each time point.

Discussion
Given our current understanding of pathophysiology of elevated IOP in glaucoma,
reducing the resistance in the trabecular outflow pathway should be a robust approach
to treatment. However, the real-world outcomes of this approach have not met the high
expectations based on the theory behind these procedures. A priori risk stratification of
patients undergoing cataract surgery with or without iStent can help enhance the
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benefit to risk ratio and help with better case selection for either procedure. Our
retrospective analysis presented here provides preliminary clues as to what
demographic and clinical variables may be of value for such models in the future.
In this study, we demonstrated improved IOP lowering success in patients undergoing
the combined CE-IS procedure compared to CE alone. However, we found that this
advantage of iStent over cataract surgery alone was not seen in our small sample of
non-Caucasian patients. The non-Caucasian group consisted of mostly Black subjects in
both CE-IS and CE patients. The incremental benefit of adding an iStent to CE was much
more apparent in the Caucasian group. This suggests that the reported IOP lowering
outcomes of Schlemm’s canal stenting and trabecular bypass procedures may be
significantly affected by the racial composition of the study population, with
predominantly Caucasian samples reporting higher success rates as compared to the
ones primarily consisting of non-Caucasian subjects. The IOP lowering benefit of
cataract surgery alone was equivalent in the 2 race-based groups in our study. To the
best of our knowledge, an effect of race on outcomes after MIGS procedures has not
been reported in the literature. In prior reports, patients were either not stratified by
race or ethnicity, or all patients were noted to be Caucasian. In a prior report by Seibold
et al, Caucasians tended to be more likely to achieve surgical success, however this
difference did not reach statistical significance (HR 0.29, CI 0.06-1.29, p=0.10).92 In
comparison to that study, our study has a larger sample and longer follow up which may
have helped reach statistical significance.
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A higher failure rate of conventional filtration procedures in Blacks may be related to a
greater number of fibroblasts and macrophages in the conjunctiva of Black patients.31
Angle surgical procedures are mechanistically expected to avoid the familiar hazards of
the subconjunctival space. The cause of failure of angle surgical procedures is not yet
established. It is possible that post-operative downstream changes in the trabecular
outflow may contribute to surgical failure despite successfully eliminating the resistance
at the inner wall of Schlemm’s canal. The likely mediators for such a mechanism can be
humoral in nature, such as inflammatory markers in the aqueous humor. We are not
aware of any known racial differences in the composition of aqueous humor. A prior
study evaluating transforming growth factor beta 2 did not find any significant
differences in its aqueous concentration between Caucasian and Black subjects.93
Systemic hypertension is more common and more severe in Black patients compared to
the general population. Several mediators have been proposed for a greater
vulnerability of Blacks patients to hypertension.94 A greater propensity for vasoreactivity
and vascular sclerosis, akin to vulnerability to systemic hypertension in Black patients,
can potentially affect the distal outflow pathways. However, contrary to this speculation
on a possible mechanism, our study did not find hypertension to be a risk factor for
failure. A prior study by Irshad et al found the Schlemm’s canal to be more posteriorly
located in eyes of Black patients as compared to Caucasians.95 Other than this report,
there are no known race-based differences in the distal outflow pathways. A study
comparing aqueous humor dynamics between Black and Caucasian patients with
primary open angle glaucoma and ocular hypertension also did not find any significant
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differences.81 Future research into differences in aqueous humor composition and flow
physiology between different race groups may provide greater insights into the causes
for failure of trabecular stenting procedures.
In evaluating the effects of systemic comorbidities on surgical success, our study found
hypertension to be a risk factor for failure to lower IOP in CE alone, but not for
combined CE-IS. Diabetes and hyperlipidemia also were not found to be risk factors for
failure. In the hypertensive subset of the study population, the lower hazard of failure
with CE-IS was no different from that of the population as a whole (HR 2.35, CI 1.105.02, p=0.03). Further research may help determine if the lower odds of IOP lowering
with CE in hypertensive subjects is related to some shared pathophysiological effects of
hypertension itself or the medications being used to treat it.
Longer axial length was associated with an increased risk of failure after CE alone or
with iStent implantation. Although all eyes included in this study had open angles on
preoperative gonioscopy, shorter eyes may be more likely to have IOP lowering after
cataract surgery, similar to eyes with narrow angles. Surprisingly, among patients with
CE alone, greater corneal curvature and lower anterior chamber depth were associated
with increased risk of failure. Empirically, one would expect a better IOP lowering effect
of CE in eyes with shallower chambers, as seen in previous studies.96,97 However, the
results of the analysis were contrary to this expectation. This suggests that there may be
more to IOP lowering with CE than a mere deepening of the anterior chamber.
Consistent with this speculation, Coh et al evaluated the effect of preoperative
biometric parameters on IOP lowering after cataract surgery in glaucomatous and non-
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glaucomatous eyes.98 At 4 months, they found shallower anterior chambers to be
associated with greater IOP lowering only in non-glaucomatous eyes, but not in
glaucomatous eyes. Also found was a significant effect of glaucoma diagnosis on the
anterior chamber depth-IOP association with a modeled 2.19 mmHg lesser IOP lowering
associated with glaucoma diagnosis. Glaucoma patients with certain lens positioning in
the eye may have greater IOP lowering benefit from CE. Based on the results of this
study’s multivariate analysis, an eye with a combination of shorter axial length, flatter
cornea and deeper anterior chamber is expected to have the most IOP lowering benefit
from CE.
Our study has several limitations that need to be considered when interpreting the
findings. This is a retrospective review of surgical success in a single academic center.
However, the severity of pathology and practice patterns at this institution likely reflect
those of any academic center in the United States. The sample size is small with a much
larger proportion of Caucasian subjects as compared to non-Caucasians, reflective of the
population demographics in the service area. To have a large enough sample to make
meaningful comparisons, the non-Caucasian group consisted of several racial and ethnic
groups. Future prospective studies can address this limitation by targeted enrollment of
specific racial and ethnic groups of interest. The current study has all the limitations of a
retrospective study with potential for selection bias and cohort effects. To minimize any
potential systematic biases, the study had consecutive inclusion of all eligible cases and
contemporary controls. The two groups were well matched for most demographic and
clinical characteristics with the exception of history of prior SLT, which was as expected,
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more prevalent in the CE-IS group. This likely reflects a selection bias for cases more in
need of IOP lowering for both SLT and iStent. However, we did not find any effect of
prior SLT on outcomes in either group in this study. Because of the retrospective design
and the absence of any washout prior to surgery, the true IOP lowering effect of either
procedure cannot be deduced from these data and could be much different from that
reported here. However, outside of the setting of a clinical trial, such data is rarely
available to a treating clinician, and treatment decisions and determination of success or
failure must be made based on the available clinical data. In that sense, the current
study is more reflective of the real-world effectiveness of the procedures evaluated
rather than their true efficacy. The systemic co-morbidities were extracted from the
problem list available in the patient’s electronic medical records. Patient’s general
medical care notes were not reviewed, and current treatment was not controlled for.
This was outside the primary scope of this preliminary study. Despite these limitations,
the current study found clinically and statistically relevant variables associated with IOP
lowering success of CE with or without iStent.
The reported findings suggest that there are significant differences in the success of CEIS but not CE alone based on race. Further research into potential racial differences in
wound healing processes at the surgical site or compensatory adjustments in distal
outflow pathways may help explain the findings of this study. Certain anatomic
configurations of the eye measurable by biometry are associated with success of CE with
or without iStent implantation. These variables can be viable candidates for inclusion in
possible personalized models for estimating success probability and thereby
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individualize the surgical recommendations for either procedure. They also can be used
to prospectively evaluate and explore other local, humoral or genetic factors to help
optimize the IOP lowering outcomes with trabecular bypass procedures.
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Conclusions
Selective laser trabeculoplasty (SLT) is one of the few treatment options in glaucoma
that directly target the trabecular meshwork and conventional outflow. In the research
presented in Chapter 1, we have shown that the IOP lowering effects of SLT are
mediated through an improvement in outflow facility. We also demonstrated that in a
multiple linear regression analysis model greater IOP lowering was associated with
lower baseline outflow facility and higher baseline aqueous flow. Thinner corneas and
younger age were of marginal association with additional IOP lowering with SLT at 3
months. This lays the groundwork for future work on using pre-operative AHD for case
selection prior to surgical procedures.
In the second chapter we established that race can be a significant determinant of AHD.
Specifically, differences in young adult Caucasians compared to similarly aged Chinese
were thinner central cornea, lower intraocular pressure, larger anterior chamber
volume and faster uveoscleral outflow rate. Differences in older adult Caucasians
compared to similarly aged Chinese were slower aqueous flow rate, lower IOP and
larger ACV. Considering all subjects together by race, Caucasian subjects had slower Fa,
thinner corneas, lower IOP, higher ACV, and faster Fu. This research makes a case for
using race as an important factor and as a leverage point for studying the effect of
biometrics and aqueous humor dynamics in studies of therapeutic IOP lowering
outcomes.
In the final chapter, using a retrospective study and survival methods, we demonstrated
that race and biometrics do indeed influence the surgical outcomes after trabecular
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bypass procedures. Overall, CE-IS patients had an increased chance of success in
lowering IOP or reducing the number of medications. Non-Caucasian patients
demonstrated a significantly higher risk of failure with CE-IS than Caucasian patients,
which was not seen with CE alone. Longer axial length was also associated with an
increased risk of failure in both surgeries in our study. Among CE patients, greater
corneal curvature and lower anterior chamber depth were associated with increased
risk of failure. Associations between IOP lowering with CE and biometric parameters
may allow for leveraging these clinical parameters for better case selection for MIGS
procedures in glaucoma patients.
Future work will use the lessons learned from this work to prospectively evaluate the
effects of biometrics and AHD on the outcomes of iStent and other trabecular bypass
procedures. This work will address the unmet needs to allow for personalization of
surgical management of mild to moderate glaucoma, by helping case selection based on
maximizing the potential IOP lowering benefit and minimizing the risk of complications.
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